The Innate Immune Receptor NLRX1 Functions as a Tumor Suppressor by Reducing Colon Tumorigenesis and Key Tumor-Promoting Signals

A. Alicia Koblansky, Agnieszka D. Truax, Rongrong Liu, Stephanie A. Montgomery, Shengli Ding, Justin E. Wilson, W. June Brickey, Marcus Mühlbauer, Rita Marie T. McFadden, Peizhen Hu, Zengshan Li, Christian Jobin, Pauline Kay Lund, Jenny P.Y. Ting

Research output: Contribution to journalArticle

  • 20 Citations

Abstract

NOD-like receptor (NLR) proteins are intracellular innate immune sensors/receptors that regulate immunity. This work shows that NLRX1 serves as a tumor suppressor in colitis-associated cancer (CAC) and sporadic colon cancer by keeping key tumor promoting pathways in check. Nlrx1-/- mice were highly susceptible to CAC, showing increases in key cancer-promoting pathways including nuclear factor κB (NF-κB), mitogen-activated protein kinase (MAPK), signal transducer and activator of transcription 3 (STAT3), and interleukin 6 (IL-6). The tumor-suppressive function of NLRX1 originated primarily from the non-hematopoietic compartment. This prompted an analysis of NLRX1 function in the Apcmin/+ genetic model of sporadic gastrointestinal cancer. NLRX1 attenuated Apcmin/+ colon tumorigenesis, cellular proliferation, NF-κB, MAPK, STAT3 activation, and IL-6 levels. Application of anti-interleukin 6 receptor (IL6R) antibody therapy reduced tumor burden, increased survival, and reduced STAT3 activation in Nlrx1-/-Apcmin/+ mice. As an important clinical correlate, human colon cancer samples expressed lower levels of NLRX1 than healthy controls in multiple patient cohorts. These data implicate anti-IL6R as a potential personalized therapy for colon cancers with reduced NLRX1.

LanguageEnglish (US)
Pages2562-2575
Number of pages14
JournalCell Reports
Volume14
Issue number11
DOIs
StatePublished - Mar 22 2016

Fingerprint

STAT3 Transcription Factor
Tumors
Colon
Carcinogenesis
Colonic Neoplasms
Interleukin-6 Receptors
Mitogen-Activated Protein Kinases
Interleukin-6
Colitis
Neoplasms
Chemical activation
Transcriptional Activation
STAT6 Transcription Factor
Gastrointestinal Neoplasms
Genetic Models
Tumor Burden
Immunity
Cell Proliferation
Antibodies
Sensors

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

The Innate Immune Receptor NLRX1 Functions as a Tumor Suppressor by Reducing Colon Tumorigenesis and Key Tumor-Promoting Signals. / Koblansky, A. Alicia; Truax, Agnieszka D.; Liu, Rongrong; Montgomery, Stephanie A.; Ding, Shengli; Wilson, Justin E.; Brickey, W. June; Mühlbauer, Marcus; McFadden, Rita Marie T.; Hu, Peizhen; Li, Zengshan; Jobin, Christian; Lund, Pauline Kay; Ting, Jenny P.Y.

In: Cell Reports, Vol. 14, No. 11, 22.03.2016, p. 2562-2575.

Research output: Contribution to journalArticle

Koblansky, AA, Truax, AD, Liu, R, Montgomery, SA, Ding, S, Wilson, JE, Brickey, WJ, Mühlbauer, M, McFadden, RMT, Hu, P, Li, Z, Jobin, C, Lund, PK & Ting, JPY 2016, 'The Innate Immune Receptor NLRX1 Functions as a Tumor Suppressor by Reducing Colon Tumorigenesis and Key Tumor-Promoting Signals' Cell Reports, vol. 14, no. 11, pp. 2562-2575. https://doi.org/10.1016/j.celrep.2016.02.064
Koblansky, A. Alicia ; Truax, Agnieszka D. ; Liu, Rongrong ; Montgomery, Stephanie A. ; Ding, Shengli ; Wilson, Justin E. ; Brickey, W. June ; Mühlbauer, Marcus ; McFadden, Rita Marie T. ; Hu, Peizhen ; Li, Zengshan ; Jobin, Christian ; Lund, Pauline Kay ; Ting, Jenny P.Y. / The Innate Immune Receptor NLRX1 Functions as a Tumor Suppressor by Reducing Colon Tumorigenesis and Key Tumor-Promoting Signals. In: Cell Reports. 2016 ; Vol. 14, No. 11. pp. 2562-2575.
@article{2460464ecedb4fea9957c8b9ba54b0ee,
title = "The Innate Immune Receptor NLRX1 Functions as a Tumor Suppressor by Reducing Colon Tumorigenesis and Key Tumor-Promoting Signals",
abstract = "NOD-like receptor (NLR) proteins are intracellular innate immune sensors/receptors that regulate immunity. This work shows that NLRX1 serves as a tumor suppressor in colitis-associated cancer (CAC) and sporadic colon cancer by keeping key tumor promoting pathways in check. Nlrx1-/- mice were highly susceptible to CAC, showing increases in key cancer-promoting pathways including nuclear factor κB (NF-κB), mitogen-activated protein kinase (MAPK), signal transducer and activator of transcription 3 (STAT3), and interleukin 6 (IL-6). The tumor-suppressive function of NLRX1 originated primarily from the non-hematopoietic compartment. This prompted an analysis of NLRX1 function in the Apcmin/+ genetic model of sporadic gastrointestinal cancer. NLRX1 attenuated Apcmin/+ colon tumorigenesis, cellular proliferation, NF-κB, MAPK, STAT3 activation, and IL-6 levels. Application of anti-interleukin 6 receptor (IL6R) antibody therapy reduced tumor burden, increased survival, and reduced STAT3 activation in Nlrx1-/-Apcmin/+ mice. As an important clinical correlate, human colon cancer samples expressed lower levels of NLRX1 than healthy controls in multiple patient cohorts. These data implicate anti-IL6R as a potential personalized therapy for colon cancers with reduced NLRX1.",
author = "Koblansky, {A. Alicia} and Truax, {Agnieszka D.} and Rongrong Liu and Montgomery, {Stephanie A.} and Shengli Ding and Wilson, {Justin E.} and Brickey, {W. June} and Marcus M{\"u}hlbauer and McFadden, {Rita Marie T.} and Peizhen Hu and Zengshan Li and Christian Jobin and Lund, {Pauline Kay} and Ting, {Jenny P.Y.}",
year = "2016",
month = "3",
day = "22",
doi = "10.1016/j.celrep.2016.02.064",
language = "English (US)",
volume = "14",
pages = "2562--2575",
journal = "Cell Reports",
issn = "2211-1247",
publisher = "Cell Press",
number = "11",

}

TY - JOUR

T1 - The Innate Immune Receptor NLRX1 Functions as a Tumor Suppressor by Reducing Colon Tumorigenesis and Key Tumor-Promoting Signals

AU - Koblansky, A. Alicia

AU - Truax, Agnieszka D.

AU - Liu, Rongrong

AU - Montgomery, Stephanie A.

AU - Ding, Shengli

AU - Wilson, Justin E.

AU - Brickey, W. June

AU - Mühlbauer, Marcus

AU - McFadden, Rita Marie T.

AU - Hu, Peizhen

AU - Li, Zengshan

AU - Jobin, Christian

AU - Lund, Pauline Kay

AU - Ting, Jenny P.Y.

PY - 2016/3/22

Y1 - 2016/3/22

N2 - NOD-like receptor (NLR) proteins are intracellular innate immune sensors/receptors that regulate immunity. This work shows that NLRX1 serves as a tumor suppressor in colitis-associated cancer (CAC) and sporadic colon cancer by keeping key tumor promoting pathways in check. Nlrx1-/- mice were highly susceptible to CAC, showing increases in key cancer-promoting pathways including nuclear factor κB (NF-κB), mitogen-activated protein kinase (MAPK), signal transducer and activator of transcription 3 (STAT3), and interleukin 6 (IL-6). The tumor-suppressive function of NLRX1 originated primarily from the non-hematopoietic compartment. This prompted an analysis of NLRX1 function in the Apcmin/+ genetic model of sporadic gastrointestinal cancer. NLRX1 attenuated Apcmin/+ colon tumorigenesis, cellular proliferation, NF-κB, MAPK, STAT3 activation, and IL-6 levels. Application of anti-interleukin 6 receptor (IL6R) antibody therapy reduced tumor burden, increased survival, and reduced STAT3 activation in Nlrx1-/-Apcmin/+ mice. As an important clinical correlate, human colon cancer samples expressed lower levels of NLRX1 than healthy controls in multiple patient cohorts. These data implicate anti-IL6R as a potential personalized therapy for colon cancers with reduced NLRX1.

AB - NOD-like receptor (NLR) proteins are intracellular innate immune sensors/receptors that regulate immunity. This work shows that NLRX1 serves as a tumor suppressor in colitis-associated cancer (CAC) and sporadic colon cancer by keeping key tumor promoting pathways in check. Nlrx1-/- mice were highly susceptible to CAC, showing increases in key cancer-promoting pathways including nuclear factor κB (NF-κB), mitogen-activated protein kinase (MAPK), signal transducer and activator of transcription 3 (STAT3), and interleukin 6 (IL-6). The tumor-suppressive function of NLRX1 originated primarily from the non-hematopoietic compartment. This prompted an analysis of NLRX1 function in the Apcmin/+ genetic model of sporadic gastrointestinal cancer. NLRX1 attenuated Apcmin/+ colon tumorigenesis, cellular proliferation, NF-κB, MAPK, STAT3 activation, and IL-6 levels. Application of anti-interleukin 6 receptor (IL6R) antibody therapy reduced tumor burden, increased survival, and reduced STAT3 activation in Nlrx1-/-Apcmin/+ mice. As an important clinical correlate, human colon cancer samples expressed lower levels of NLRX1 than healthy controls in multiple patient cohorts. These data implicate anti-IL6R as a potential personalized therapy for colon cancers with reduced NLRX1.

UR - http://www.scopus.com/inward/record.url?scp=84962543071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962543071&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2016.02.064

DO - 10.1016/j.celrep.2016.02.064

M3 - Article

VL - 14

SP - 2562

EP - 2575

JO - Cell Reports

T2 - Cell Reports

JF - Cell Reports

SN - 2211-1247

IS - 11

ER -